Landos Biopharma started at outperform with $33 stock price target at Raymond James

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Landos Biopharma Inc.

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply